Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edaravone + dexborneol with recanalization in acute ischemic stroke
ChiCTR2200055910Phase 4Not yet recruiting
- Sponsor
- Putian First Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of edaravone dexborneol in ischemic stroke (2 arms), sponsored by Putian First Hospital. Primary endpoint: Rate of good prognosis at 90 days. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
edaravone dexborneol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2200055910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055910.